Immunotherapy for acute-on-chronic liver failure

Han Ying; Cui LiNa; Guo GuanYa

doi:10.3969/j.issn.1001-5256.2017.09.010

Issue 9

Sep. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(9): 1677-1682

PDF( 1663 KB)

Immunotherapy for acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2017.09.010

Xijing Hospital of Digestive Disease, Fourth Military Medical University

Received Date: 2017-06-21
Published Date: 2017-09-20

Abstract

Abstract

Inflammatory response and immune dysfunction play important roles in the progression of acute-on-chronic liver failure ( ACLF) and may lead to systemic inflammatory response syndrome. Excessive inflammatory and immune response may result in increased susceptibility to infection and finally lead to multiple organ dysfunction syndrome ( MODS) . Elimination of liver injury and correction of immune dysfunction can prevent sepsis and/or MODS and improve patients'survival. Up to now, immunotherapy for ACLF has not been recommended in related guidelines. However, as an important pathophysiological change of ACLF and a key event closely associated with incidence rate and mortality rate, persistent activation of hepatic and systemic inflammatory response and immune cell dysfunction urges us to consider immunoregulatory treatment, in order to block and reverse disease progression. This article introduces potential immunoregulatory drugs for the treatment of ACLF, including albumin, glucocorticoids, granulocyte colony-stimulating factor, artificial liver support system, and mesenchymal stem cell transplantation, and discusses some promising targets for immunotherapy.
- liver failure,
- multiple organ failure,
- immunotherapy,
- therapy

FullText(HTML)

References(28)

References

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, CMA.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[2]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.

[3]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterology, 2013, 144 (7) :1426-1437, 1437.e1-9.

[4] SARIN SK, CHOUDHURY A.Acute-on-chronic liver failure:terminology, mechanisms and management[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (3) :131-149.

[5]XING T, LI L, CAO H, et al.Altered immune function of monocytes in different stages of patients with acute on chronic liver failure[J].Clin Exp Immunol, 2007, 147 (1) :184-188.

[6]MOOKERJEE RP, STADLBAUER V, LIDDER S, et al.Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome[J].Hepatology, 2007, 46 (3) :831-840.

[7]ZHANG Z, ZOU ZS, FU JL, et al.Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure[J].J Hepatol, 2008, 49 (3) :396-406.

[8] ZHAO J, ZHANG JY, YU HW, et al.Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J].Cell Mol Immunol, 2012, 9 (5) :417-422.

[9]BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterology, 2015, 148 (3) :603-615.

[10]SOLE C, SOLA E, MORALES-RUIZ M, et al.Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis[J].Sci Rep, 2016, 6:32341.

[11]FISCHER J, SILVA TE, SOARES ESP, et al.From stable disease to acute-on-chronic liver failure:Circulating cytokines are related to prognosis in different stages of cirrhosis[J].Cytokine, 2017, 91:162-169.

[12]FAN Z, ENQIANG C, YAO DL, et al.Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virusrelated acute-on-chronic liver failure treated with an artificial liver support system[J].PLo S One, 2017, 12 (4) :e175332.

[13]CHOUDHURY A, KUMAR M, SHARMA BC, et al.Systemic inflammatory response syndrome in acute on chronic liver failure-relevance of'golden window'-a prospective study[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]

[14]GARCIA-MARTINEZ R, ANDREOLA F, MEHTA G, et al.Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J].J Hepatol, 2015, 62 (4) :799-806.

[15]ZHAO J, ZHANG JY, YU HW, et al.Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J].Cell Mol Immunol, 2012, 9 (5) :417-422.

[16]DUAN XZ, LIU FF, TONG JJ, et al.Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure[J].World J Gastroenterol, 2013, 19 (7) :1104-1110.

[17]ROLANDO N, CLAPPERTON M, WADE J, et al.Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure[J].Eur J Gastroenterol Hepatol, 2000, 12 (10) :1135-1140.

[18]KEDARISETTY CK, ANAND L, BHARDWAJ A, et al.Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis[J].Gastroenterology, 2015, 148 (7) :1362-1370.

[19]CHAVEZ-TAPIA NC, MENDIOLA-PASTRANA I, ORNELAS-ARROYO VJ, et al.Granulocyte-colony stimulating factor for acuteon-chronic liver failure:systematic review and meta-analysis[J].Ann Hepatol, 2015, 14 (5) :631-641.

[20]MAO WL, CHEN Y, CHEN YM, et al.Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange[J].J Clin Gastroenterol, 2011, 45 (6) :551-555.

[21]FINKENSTEDT A, NACHBAUR K, ZOLLER H, et al.Acute-on-chronic liver failure:excellent outcomes after liver transplantation but high mortality on the wait list[J].Liver Transpl, 2013, 19 (8) :879-886.

[22]BANARES R, NEVENS F, LARSEN FS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure:the RELIEF trial[J].Hepatology, 2013, 57 (3) :1153-1162.

[23]CUI L, SHI Y, HAN Y, et al.Immunological basis of stem cell therapy in liver diseases[J].Expert Rev Clin Immunol, 2014, 10 (9) :1185-1196.

[24]LIN BL, CHEN JF, QIU WH, et al.Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure:a randomized controlled trial[J].Hepatology, 2017, 66 (1) :209-219.

[25]LI YH, XU Y, WU HM, et al.Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir:a 24-month prospective study[J].Stem Cell Rev, 2016, 12 (6) :645-653.

[26]YANG H, OCHANI M, LI J, et al.Reversing established sepsis with antagonists of endogenous high-mobility group box 1[J].Proc Natl Acad Sci U S A, 2004, 101 (1) :296-301.

[27]LI X, WANG LK, WANG LW, et al.Blockade of high-mobility group box-1 ameliorates acute on chronic liver failure in rats[J].Inflamm Res, 2013, 62 (7) :703-709.

[28] BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterology, 2015, 148 (3) :603-615.

Relative Articles

[1]	Jiang LI, Xing DAI, Dazhi TIAN, Wentao JIANG, Zhongyang SHEN. Advances in the clinical research on liver transplantation in treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1188-1191. doi: 10.3969/j.issn.1001-5256.2022.05.045
[2]	Wang YuMing, Zhao XueLan. More attention to hotspots and difficulties in research on liver failure[J]. Journal of Clinical Hepatology, 2018, 34(9): 1819-1823. doi: 10.3969/j.issn.1001-5256.2018.09.001
[3]	Meng QingHua. Timing of glucocorticoid therapy for liver failure[J]. Journal of Clinical Hepatology, 2017, 33(9): 1683-1686. doi: 10.3969/j.issn.1001-5256.2017.09.011
[4]	Gu TianYi, Lu LunGen. Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens[J]. Journal of Clinical Hepatology, 2017, 33(6): 1165-1168. doi: 10.3969/j.issn.1001-5256.2017.06.032
[5]	Lin Feng. Research advances in clinical diagnosis,prognostic evaluation,and treatment of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1678-1683. doi: 10.3969/j.issn.1001-5256.2016.09.009
[6]	Ma Zhen, Wu Yun. Current status of liver failure treatment[J]. Journal of Clinical Hepatology, 2016, 32(9): 1668-1672. doi: 10.3969/j.issn.1001-5256.2016.09.007
[7]	Zhang Yong, Zeng WeiZheng, Wang YunXia, Weng Min, Zheng ShuMei, Jiang MingDe. Effect of continuous blood purification in treatment of patients with severe acute pancreatitis and multiple organ dysfunction syndrome[J]. Journal of Clinical Hepatology, 2016, 32(2): 320-323. doi: 10.3969/j.issn.1001-5256.2016.02.025
[8]	Zheng HuanWei, Li Li, Bai GeLan. Clinical efficacy and problems of artificial liver support system in treatment of liver failure[J]. Journal of Clinical Hepatology, 2015, 31(9): 1411-1414. doi: 10.3969/j.issn.1001-5256.2015.09.011
[9]	Ma LinJie, Chen Gang, Hu ZongQiang, Liu Hong, Wang DongDong, Fang He, Jin Xiong. Mechanism of treatment of acute-on-chronic liver failure with mesenchyaml stem cells[J]. Journal of Clinical Hepatology, 2015, 31(9): 1505-1508. doi: 10.3969/j.issn.1001-5256.2015.09.037
[10]	Liu Hong, Chen Gang, Gan XueMei. Research advances in new approaches to treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(9): 1496-1500. doi: 10.3969/j.issn.1001-5256.2015.09.035
[11]	Yang JianLe, Huang JianRong. Application of artificial liver support system in treatment of liver failure[J]. Journal of Clinical Hepatology, 2015, 31(9): 1405-1410. doi: 10.3969/j.issn.1001-5256.2015.09.010
[12]	Wang QingHai, Tian Yi. Clinical efficacy of modulation of intestinal microecology and plasmapheresis for preventing and treating multiple organ failure in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1426-1429. doi: 10.3969/j.issn.1001-5256.2015.09.015
[13]	Wang Xian, Wang ShaoYang, Huang DeDong, Chen Jian, Chen DeLiang. Analysis of short-term prognostic factors in patients with HBV-related acute-on-chronic liver failure treated with artificial liver support system[J]. Journal of Clinical Hepatology, 2014, 30(4): 367-369. doi: 10.3969/j.issn.1001-5256.2014.04.020
[14]	Cui LiJian, Liu RuiXia, Wang Yan, Yin ChengHong. Clinical features and treatment of organ failure in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2014, 30(8): 726-729. doi: 10.3969/j.issn.1001-5256.2014.08.006
[15]	Zhang AiMin, Xin ShaoJie. Virus infection and liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 729-731.
[16]	Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
[17]	Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
[18]	Li ShuangXing, Shi LiJun, Wang XiuJie. Effects of bone marrow mesenchymal stem cells transplantation into rats with acute liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 624-626.
[19]	Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	尹恒，杨蕊西，寇国先，阮军. 甲泼尼龙治疗HBV相关慢加急性肝衰竭的疗效及安全性的Meta分析. 中西医结合肝病杂志. 2023(11): 1017-1021 .
2.	刘亚芬，孙莉，谢雁鸣，庄严. 真实世界丹参川芎嗪注射液用于治疗肝功能异常的回顾性研究. 世界中西医结合杂志. 2022(08): 1649-1654 .
3.	刘勇，周彪. 牛黄清瘟饮治疗乙型肝炎相关慢加急性肝衰竭(肝瘟)前期(热毒血瘀证)临床疗效及对凝血功能的影响. 四川中医. 2021(03): 129-132 .
4.	陈微，孙克伟，叶锡勇. 附子理中汤对慢加急性肝衰竭大鼠肝损伤的影响及其作用机制. 山西医科大学学报. 2021(07): 862-867 .
5.	涂俊才，周平，楼莲青. 血必净对乙型肝炎相关慢加急性肝衰竭早期患者炎症因子、肝功能及凝血功能的影响. 浙江中西医结合杂志. 2020(05): 382-385 .
6.	李永芳，李娟，吴慧慧，蔡伟，刘芸野. 胸腺肽α1对乙型肝炎相关慢加急性肝衰竭疗效分析. 肝脏. 2019(06): 677-679 .
7.	范红顺，熊志娇，马超，邱少霞，沈莉华. 小剂量激素辅助双重血浆分子吸附治疗早期慢加急性肝功能衰竭的疗效及抗SLA水平观察. 肝脏. 2019(07): 770-773 .
8.	高艺，梁志军，符健. IL-35对慢加急性肝衰竭患者外周血CD8~+ T淋巴细胞功能的影响. 临床肝胆病杂志. 2019(09): 2011-2016 . 本站查看
9.	李娜，顾欢，朱英，赵钢. 肝衰竭治疗的最新进展. 医学与哲学(B). 2018(08): 50-54 .
10.	田玉球，周宁，蒋永芳. 粒细胞集落刺激因子联合恩替卡韦治疗早期乙肝慢加急性肝衰竭的效果及对AngⅡ、TNF-α和IL-10的影响. 中国医药导报. 2018(17): 139-142 .
11.	吴贻琛，姚红宇，王开利，姜祺予，刘畅，邢汉前，刘素霞，游绍莉，赵军. 血浆置换对慢加急性(亚急性)肝衰竭患者外周血CD34~+细胞生物学活性的影响. 临床肝胆病杂志. 2018(11): 2383-2387 . 本站查看

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2674) PDF downloads(478)

Immunotherapy for acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2017.09.010